新型冠状病毒疫苗在慢性肾脏病患者中的效果评价

<正>自新型冠状病毒肺炎（COVID-19）爆发以来，其迅速传播的特点和多种突变变种的出现，对人类健康和经济发展产生了巨大的影响。COVID-19的病原体新型冠状病毒（SARS-Co V-2）可通过其刺突蛋白（S）和血管紧张素转换酶2(ACE2)的相互作用进入细胞，激活NF-κB相关的炎症小体，

The Effectiveness Evaluation of COVID-19 Vaccines in Chronic Kidney Disease Patients

Since the breakout of Corona Virus Disease 2019 (COVID-19), the rapid spread of it and the emergence of many mutant variants have had a tremendous impact on human health and economic development. Critical illness of COVID-19 easily occurs in the elderly and vulnerable individuals, such as those with chronic kidney disease (CKD). Due to long-term use of immunosuppressants, patients with CKD are at high risk of infection, including dialysis or even kidney recipients. In order for this group of people to develop adaptive immunity against SARS-CoV-2, vaccination against the spike protein is important. But the chronic use of immunosuppressants might disturb the efficacy of COVID-19 vaccines. On the basis of current researches, the immune compromised status of CKD patients might decrease neutralizing antibody development after a single dose of a specific vaccine, boosting dosage more than the protocol might increase the titer of the neutralizing antibody in CKD patients. Further evidence is needed to understand the factors disturbing the immunogenicity of the COVID-19 vaccines. As CKD patients are relatively immunocompromised, in addition to taking precautions during the COVID-19 pandemic, this population should receive the recommended dose of vaccines to achieve adaptive immunity to SARS-CoV-2.